MADRID, 22 September (EUROPA PRESS) –
Merck and Pfizer announced that the New England Journal of Medicine (NEJM) in its online edition has published the results of the Phase III study ‘JAVELIN Bladder 100’ which describes the efficacy and safety of ‘Bavencio’ (avelumab) for the treatment of first-line maintenance in various subgroups of patients with locally advanced or metastatic urothelial carcinoma (UC) and patient-reported outcomes (PRO).
In June, the US Food and Drug Administration (FDA) approved avelumab for the maintenance treatment of patients with locally advanced or metastatic UC who have not developed platinum first-line chemotherapy, based on the results. from ̵
In the study, which was published together with the presentation of further analyzes at the Virtual Society of the European Society for Medical Oncology (ESMO) 2020, avelumab with best supportive therapy (BSC), significant improvement in median overall survival (OS) compared to BSC monotherapy in the two primary populations of all randomized patients and patients with PD-L1-positive tumors and significantly more patients receiving avelumab as treatment. Frontline maintenance lived on after a year.
These data, which support recent FDA approval and updates from the National Comprehensive Cancer Network (NCCN) and the ESMO guidelines, show that first-line treatment with avelumab can dramatically change practice. clinic for the treatment of patients with locally advanced or metastatic urothelial carcinoma “, says the leader in genitourinary oncology, a leader in solid tumor research at the Barts Cancer Institute at Queen Mary University of London and the head of the Barts Cancer Center of London, Thomas Powles.
Similarly, it showed that the increase in overall survival with the maintenance regimen avelumab was observed in all subgroups studied, this increase in overall survival was obtained without adversely affecting the quality of life. patients.
“TV nerd. Social media specialist. Creator. Passionate writer. Extreme travel ninja. Total contractor. Internetaholic ”.